Companies: 10,795·Total market cap: $144.5T
TransCode Therapeutics, Inc.

TransCode Therapeutics, Inc.

RNAZNASDAQHealthcare● Active
$4.68
$-0.92(-16.43%)
Market Cap$4447409
P/E Ratio—
52W High$20.99
52W Low$3.82
SEC Filings

TransCode Therapeutics, Inc. (RNAZ) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001829635 · RNAZ · NASDAQ · as of Jun 8, 2026

Filing snapshot

296
Total Filings
8-K
Latest Form
2026-06-03
Most Recent
2021
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001829635 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-04-30
Fiscal Year End
Apr 30, 2026
Accession No.
0001104659-26-052941
Primary Document
rnaz-20251231x10ka.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001829635 · Accession 0001104659-26-052941

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-15
View 10-Q on SEC
8-KCurrent Report
FORM 8-K
2026-06-03Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
8-KCurrent Report
FORM 8-K
2026-06-03
View
ARSARS
ARS
2026-06-02
View
DEF 14AProxy Statement
DEF 14A
2026-06-02
View
8-KCurrent Report
FORM 8-K
2026-06-01
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-05-26
View
8-K/ACurrent Report (Amended)
FORM 8-K/A
2026-05-26
View
8-KCurrent Report
FORM 8-K
2026-05-22
View
EFFECTEFFECT
EFFECT
2026-05-19
View
EFFECTEFFECT
EFFECT
2026-05-19
View
10-QQuarterly Report
10-Q
2026-05-15
View
PRE 14APRE 14A
PRE 14A
2026-05-08
View
S-1IPO Registration Statement
S-1
2026-05-01
View
S-3Shelf Registration
FORM S-3
2026-04-30
View
10-K/AAnnual Report (Amended)
10-K/A
2026-04-30
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-04-20
View
Showing 1–15 of 266 filingsForm 4 / 144 hidden· 296 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001829635  |  Exchange: NASDAQ · Healthcare

TransCode Therapeutics, Inc. (NASDAQ: RNAZ) has submitted 296 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2021. As a Healthcare sector company with CIK 0001829635, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is TransCode Therapeutics, Inc.'s most comprehensive regulatory disclosure. The most recent TransCode Therapeutics, Inc. 10-K was filed on 2026-04-30 for fiscal year ending 2026. Historical RNAZ 10-K annual reports are available from 2020 through 2026.

Investors researching TransCode Therapeutics, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08
Related Companies SEC Filings — Healthcare
GLTO SEC Filings →PHIO SEC Filings →KPRX SEC Filings →BOLT SEC Filings →INAB SEC Filings →APVO SEC Filings →APRE SEC Filings →HCWB SEC Filings →
→ RNAZ Financials→ RNAZ Earnings→ RNAZ Insider Trades

Frequently Asked Questions

RNAZ SEC Filings · 8 questions

TransCode Therapeutics, Inc. (RNAZ) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 296 filings and access original documents at no cost. TransCode Therapeutics, Inc.'s CIK is 0001829635.

RNAZ SEC filingsTransCode Therapeutics, Inc. SEC documentsfind RNAZ 10-K